Condition
Neisseria Meningitides Meningitis
Total Trials
2
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
2 treatments under study, led by Yuxi Walvax Mpv Acyw Vaccine
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
Phase 4 (1)
Trial Status
Unknown1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (2)
Showing 2 of 2 trials
NCT04450498Phase 4CompletedPrimary
A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years
NCT04594785Unknown
Evaluation of Post Infectious Inflammatory Reaction (PIIR) Concerning Children After Streptococcus Pneumoniae, Streptococcus Pyogenes and Neisseria Meningococcus Invasive Infection
Showing all 2 trials
Research Network
Common Treatments
- Yuxi Walvax Mpv Acyw Vaccine1
- Sanofi Pasteur Menactra Vaccine1
Active Sponsors
- Walvax Biotechnology Co., Ltd.1
- University Hospital, Montpellier1
Top Investigators
University Hospital, Montpellier
Director General
Related Conditions
- Streptococcus Pneumonia1
- Streptococcus Pyogenes Infection1